novo nordisk cagrilintide Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial? Novo's Amylin Injectable Cagrilintide Hits
Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial BioSpace Weight loss: New drug CagriSema leads to 14% weight loss in trial Obesity drug candidate Cagrilintide begins late stage program at Novo Nordisk Novo Nordisk's next gen obesity drug underperforms in trial Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors.
Pay in 4 interest-free payments of $5.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


